Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

Not Applicable

Completed

• Conditions: Epilepsy, Tonic-Clonic; Epilepsies, Partial
• Interventions: Device: Microburst Stimulation

• Registration Number: NCT03446664
• Lead Sponsor: LivaNova

Brief Summary

Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-02-09
• Study First Submitted QC: 2018-02-20
• Study Start: 2018-02-27
• Study First Posted: 2018-02-27
• Primary Completion: 2021-07-30
• Study Completion: 2021-10-27
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-21
• Last Update Posted: 2022-10-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

1. Clinical diagnosis of medically refractory epilepsy with primary generalized tonic-clonic seizures (limited to 20 subjects) or partial onset seizures including complex partial seizures with or without secondary generalization (limited to 20 subjects).
2. Must be on adjunctive antiepileptic medications.
3. Willing and capable to undergo multiple evaluations with functional magnetic resonance imaging (fMRI), electroencephalogram (EEG) and electrocardiogram (ECG).

4(A) For subjects with partial onset seizures: An average of ≥ 3 countable seizures per month based on seizure diary during the 3 month baseline period and no seizure-free interval greater than 30 days during those 3 months.

4(B) For subjects with PGTCs: Have at least ≥ 3 countable seizures during the 3 month baseline period. Note: Each seizure within a cluster may be counted as separate seizures.

5. 12 years of age or older.

6. Subject is a male or non-pregnant female adequately protected from conception. Females of childbearing potential must use an acceptable method of birth control.

7. Provide written informed consent-assent/Health Insurance Portability and Accountability Act (HIPAA) authorization and self-reported measures with minimal assistance as determined by the investigator.

Exclusion Criteria

1. Currently using, or are expected to use, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy.
2. A VNS Therapy System implant would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the subject.
3. A planned procedure that is contraindicated for VNS therapy.
4. History of implantation of the VNS Therapy System.
5. Currently receiving treatment from an active implantable medical device.
6. Presence of contraindications to MRI per the MRI subject screening record.
7. Known clinically meaningful cardiovascular arrhythmias currently being managed by devices or treatments that interfere with normal intrinsic heart rate responses (e.g., pacemaker dependency, implantable defibrillator, beta adrenergic blocker medications).
8. History of chronotropic incompetence (commonly seen in subjects with sustained bradycardia [heart rate < 50 bpm]).
9. Cognitive or psychiatric deficit that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments.
10. History of status epilepticus within 1 year of study enrollment.
11. Dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the past 2 years, based on history. Tests for drug or alcohol use will not be administered.
12. Currently being treated with prescribed medication that contains cannabis or cannabis related substance including recreational use.
13. Any history of psychogenic non-epileptic seizures.
14. Currently participating in another clinical study without LivaNova written approval.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Microburst Stimulation	Microburst Stimulation	Microburst stimulation to tolerability and effectiveness

Primary Outcome Measures

Name	Time	Method
Safety Primary Endpoint: Occurrence of stimulation related Adverse Events	Up to 12 months study visit	Assess stimulation/device related adverse events at follow-up visits month 6 and 12.
Efficacy Primary Endpoint: Percent change from baseline in seizure frequency	Up to 12 months study visit	For the primary endpoint, the change in the seizure frequency per month compared to baseline will be evaluated for each subject at follow-up visits month 6 and 12.

Secondary Outcome Measures

Name	Time	Method
Change from baseline in seizure frequency per month based on seizure diary provided by the sponsor	Up to 12 months study visit
All adverse events	Up to 12 months visit
Change from baseline in seizure severity	Up to 12 months study visit	As measured by the Seizure Severity Questionnaire (SSQ) scale (Cramer, 2002).
Change from baseline in antiepileptic drug (AED) load	Up to 12 months study visit	Estimated as the sum of the prescribed daily dose (PDD)/defined daily dose (DDD) ratios for each AED included in the treatment regimen (Deckers et al., 1997), where DDD (WHO ATC/DDD index) corresponds to the assumed average therapeutic daily dose of a drug used for its main indication.
Suicidality as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)	Up to 12 months study visit
Change from baseline in quality of life	Up to 12 months study visit	As measured by the QOLIE-31-P for adults 18 years and older (Cramer et al.; 1998) and QOLIE-AD-48 for adolescents 12 to 17 years (Cramer et al.; 1999).

Trial Locations

Locations (9)

Mayo Clinic Florida; 🇺🇸 Jacksonville, Florida, United States

Weil-Cornell Medical College; 🇺🇸 Ithaca, New York, United States

Rush University; 🇺🇸 Chicago, Illinois, United States

Northwestern University; 🇺🇸 Evanston, Illinois, United States

Duke University; 🇺🇸 Durham, North Carolina, United States

Ghent University Hosptial; 🇧🇪 Ghent, Belgium

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

University of Denver Colorado; 🇺🇸 Denver, Colorado, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States